NVCR News and Press, NovoCure Limited From 04/07/21

NovoCure invented a new type of cancer treatment based on TTF (tumor treating fields). They use electricity to disrupt the division of cancer cells. The company is working to expand use cases via FDA approval, which could drive growth for years to come. The stock isn't "cheap" but...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2021 on Thursday, April 29, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the thr...

Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q4 2020 Earnings Call Feb 25, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q4 2020 Earnings Call Transcript

Shares of NovoCure (NASDAQ: NVCR) were sinking 12.5% lower as of 3 p.m. EST on Thursday. The decline came after the company delayed several clinical studies and Evercore ISI analyst Vijay Kumar wrote to clients that NovoCure's growth is set to taper off. Kumar's gloomy predictio...

NovoCure Limited. (NVCR) Q4 2020 Results Earnings Conference Call February 25, 2021, 08:00 AM ET Company Participants Gabrielle Fernandes - Director, IR William Doyle - Executive Chairman Asaf Danziger - President, CEO & Director Ashley Cordova - CFO & VP, IR Ely Benaim - Chief Medica...

The following slide deck was published by NovoCure Limited in conjunction with their 2020 Q4 earnings call. For further details see: NovoCure Limited 2020 Q4 - Results - Earnings Call Presentation

NovoCure (NVCR): Q4 GAAP EPS of $0.04 misses by $0.09.Revenue of $143.95M (+45.1% Y/Y) beats by $0.46M.There were 3,411 active patients, representing 17% growth Y/Y.The Co. expects growth in R&D to continue into 2021 as they work to advance the pipeline programs and increase acceptance of...

Quarterly net revenues of $144.0 million, representing 45 percent growth versus the fourth quarter 2019 and 9 percent growth versus the third quarter 2020 Quarterly net income of $4.9 million with $0.05 in earnings per share Novocure (NASDAQ: NVCR) today reported fin...

NovoCure (NASDAQ:NVCR) is scheduled to announce Q4 earnings results on Thursday, February 25th, before market open.The consensus EPS Estimate is $0.13 and the consensus Revenue Estimate is $143.49M (+44.6% Y/Y).Over the last 1 year, NVCR has beaten EPS estimates 25% of the time and has beaten...

Delcath Systems develops drug/device combos to treat liver cancers. The company’s stock is underappreciated due to past clinical failures and a de-listing despite promising clinical data. Delcath updated the trial design for its lead product to address past issues around pa...